NOVAN INC (NASDAQ: NOVN) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare NOVAN INC to similar businesses based on the strength of its institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Institutional and Insider Ownership
6.1% of NOVAN INC shares are held by institutional investors. Comparatively, 66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.7% of NOVAN INC shares are held by company insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares NOVAN INC and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|NOVAN INC||$768,999.00||-$49.04 million||-0.81|
|NOVAN INC Competitors||$2.40 billion||$906.33 million||3.75|
NOVAN INC’s competitors have higher revenue and earnings than NOVAN INC. NOVAN INC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and target prices for NOVAN INC and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NOVAN INC Competitors||97||364||956||28||2.63|
NOVAN INC currently has a consensus price target of $17.24, indicating a potential upside of 167.33%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.04%. Given NOVAN INC’s stronger consensus rating and higher possible upside, research analysts plainly believe NOVAN INC is more favorable than its competitors.
This table compares NOVAN INC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NOVAN INC Competitors||-538.85%||-41.85%||-24.81%|
NOVAN INC competitors beat NOVAN INC on 6 of the 11 factors compared.
About NOVAN INC
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
Receive News & Ratings for NOVAN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVAN INC and related companies with MarketBeat.com's FREE daily email newsletter.